‘Significant Discounts’ For Biosimilars Could Disrupt US Market

Pacific Research Institute Report Urges Removal Of Barriers To Price Competition

 
• By Dave Wallace

With the launch of rivals to Humira looming in 2023, removing barriers to free pricing and reforming formularies will be essential to promote biosimilar competition in the US, according to Wayne Winegarden of the Pacific Research Institute.

Money Dollar Note Disruption Concept
Reforms to the rebate system could allow lower-priced biosimilars to capture greater market share, Winegarden believes • Source: Shutterstock

More from Biosimilars

More from Products